Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 1 2014
Print

Financial Report: Jubilant Life Sciences



Published February 6, 2012
Jubilant Life Sciences

3Q Revenues: $219.8 million (+25%)

3Q Loss: $15.8 million (earnings were $9.4 million 3Q10)

YTD Revenues: $622.9 million (+21%)

YTD Earnings: $15.8 million (-56%)

Comments: International business grew 28% in the quarter, contributing 71% to sales at $155.1 million. Sales from Regulated Markets of U.S., Canada, Europe and Japan were $128.4 million (+43%), accounting for 58% of sales. YTD International business accounted for $435.0 million (+22%), contributing 70% to sales. Regulated Markets accounted for $359.6 million (+33%), contributing 58% to sales. In the quarter revenues from Life Science Products were $175.3 million (+24%) and YTD were $493.3 million (+23%). Life Science Services revenue was $44.5 million in the quarter (+32%) and $129.4 million YTD (+15%). CMO revenue, which includes the Jubilant HollisterStier business, was up 18% at $93.4 and Drug Discovery and Development Solutions reported $34.2 million in sales, up 9%. Earnings for the quarter fell because of a $31 million charge related to currency movement between the rupee and the dollar.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On